Skip to main content

fesoterodine

Generic: FESOTERODINE FUMARATE·Brand: FESOTERODINE FUMARATE, TOVIAZ, Toviaz

fesoterodine: developed by 1 company · 1 FDA decision.

fesoterodine evidence translation

What we can confirm

1 FDA record

What it means

Source-backed records connect fesoterodine to PFE; that link alone does not prove the drug works.

What to watch

Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected

Prepared research question

How could fesoterodine → PFE affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

Development Pipeline (2)
CompanyPhase
PFIZER INC (PFE)Approved
PFIZER INC (PFE)Approved
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE Toviaz is indicated for the treatment of: • Overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency. ( 1.1 ) • Neurogenic detrusor overactivity (NDO) in pediatric patients 6 years of age and older and weighing greater than 25 kg. ( 1.2 ) 1.1 Adult Overactive Bladder Toviaz is indicated for the treatment of overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency. 1.2 Pediatric Neuro(PFE)FDA ↗
NDA022030Type 1 - New Molecular EntityStandardOralTablet, Extended Release

Frequently asked questions

Who is developing fesoterodine?

fesoterodine is being developed by PFIZER INC.

What is fesoterodine's latest FDA decision?

The most recent tracked FDA decision for fesoterodine is Approval for 1 INDICATIONS AND USAGE Toviaz is indicated for the treatment of: • Overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency. ( 1.1 ) • Neurogenic detrusor overactivity (NDO) in pediatric patients 6 years of age and older and weighing greater than 25 kg. ( 1.2 ) 1.1 Adult Overactive Bladder Toviaz is indicated for the treatment of overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency. 1.2 Pediatric Neuro, dated October 31, 2008.